Free Newsletter
Superdrug given wider scope in Europe
Superbugs, beware. European regulators have unleashed the Novartis drug Cubicin on two more dangerous hospital-acquired infections, including those caused by multidrug-resistant staph, or MRSA. Cubicin is first in a new class of antibiotics known as cyclic lipopeptides designed to prevent bacteria from releasing toxins into the bloodstream.
The two new indications approve Cubicin for use against staph infections of the heart valve and bloodstream. Studies showed the drug as equally effective as current standard-of-care treatments with vancomycin or penicillin-plus-gentamicin - with fewer instances of impaired kidney function, the company said.
- check out the Novartis press release
- and here's more from CNN MoneyÂ
Related Articles:
Cubist seeks expanded label for Cubicin. Report
Drug-resistant superbugs drive blockbuster antibacterials. Report
Indian court spurns Novartis on patent challenge. Report
NCI cancels Novartis cancer study. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: